← Leaderboards
Henryk Dudek
Dicerna Pharmaceuticals, Inc.
$2,500,000
Attributed
$5,000,000
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2018–21$2M$1.5M$1M$500K$0
'18
'19
'20
'21
Funding mix
By agency
NIH$5,000,000 · 1
By mechanism
U44$5,000,000 · 1
Top collaborators
- Bob D. Brown4 shared
Most similar at Dicerna Pharmaceuticals, Inc.
Same institution · by research overlap
- Bob D. Brown$4,682,738
Others in their field
Other Emerging Leaders on “Acamprosate”
- Stacy Ann Sterling · Kaiser Foundation Research Institute$3,434,860
- Brent Keith Blackburn · Amygdala Neurosciences, Inc.$2,055,000
- Stephan Reinhard Lindner · Oregon Health & Science University$1,389,863
- Ming-Fen Ho · Mayo Clinic Rochester$1,069,726
- Eric G. Devine · Boston Medical Center$939,097
- Fares Qeadan · University Of Utah$770,000
Research focus
AcamprosateAdultAcetaldehydeAdverse EventAffectAlcohol Abuse TherapyAlcohol ConsumptionAlcoholsAlcohol Use DisorderAldehyde DehydrogenasesAnimalsAntibodiesAssay DevelopmentBehavior TherapyBinding ProteinsBinge DrinkingBiodistributionChronicClinical DevelopmentClinical TrialsCompliance BehaviorCostCyclic GmpDesign
Grant awards (4)
Development of an ALDH2-Targeting RNAi Therapeutic for Alcohol Use Disorders$1,500,000
U44 · FY2021 · AA · contact PI
Development of an ALDH2-Targeting RNAi Therapeutic for Alcohol Use Disorders$1,500,000
U44 · FY2020 · AA · contact PI
Development of an ALDH2-Targeting RNAi Therapeutic for Alcohol Use Disorders$1,000,000
U44 · FY2019 · AA · contact PI
Development of an ALDH2-Targeting RNAi Therapeutic for Alcohol Use Disorders$1,000,000
U44 · FY2018 · AA · contact PI